肝硬化合并糖尿病的中西医结合诊治

赵长青

doi:10.3969/j.issn.1001-5256.2022.09.006

肝硬化合并糖尿病的中西医结合诊治

DOI: 10.3969/j.issn.1001-5256.2022.09.006

赵长青^, ,

上海中医药大学附属曙光医院肝病二科，上海 201103

基金项目:

国家自然科学基金 (81673780)

利益冲突声明：作者声明不存在利益冲突。

详细信息

通信作者:
赵长青，cathy090909@126.com

计量
- 文章访问数: 566
- HTML全文浏览量: 211
- PDF下载量: 65
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-30
- 录用日期: 2022-06-30
- 出版日期: 2022-09-20

Integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis with diabetes

Changqing ZHAO^{,
,}

Second Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201103, China

Research funding:

National Natural Science Foundation of China (81673780)

More Information

Corresponding author: ZHAO Changqing, cathy090909@126.com(ORCID: 000-0002-7925-1835)

摘要

摘要: 肝源性糖尿病(HD)是肝硬化的一种常见并发症，可降低患者生存率，增加其他并发症的发生风险，其病因、发病机制、诊断方法等都有别于2型糖尿病。目前国内外尚无针对HD治疗的指南。中医对HD的研究认识虽然逐渐加深，但是针对其病因病机，乃至辨证分型均未达成共识。本文回顾了近年HD的相关中西医研究进展，为临床医生制定适合患者的中西医结合个体化诊治措施提供参考。
- 肝硬化 /
- 糖尿病 /
- 中西医结合疗法
Abstract: Hepatogenous diabetes (HD) is a common complication of liver cirrhosis and can reduce survival rate and increase the risk of other complications. It differs from type 2 diabetes in terms of etiology, pathogenesis, and diagnostic methods. There are currently no guidelines for HD treatment in China and globally. Although the understanding of HD in traditional Chinese medicine is gradually deepened, no consensus has been reached on its etiology, pathogenesis, and syndrome differentiation. This article reviews the traditional Chinese and Western medicine research on HD in recent years, so as to provide a reference for clinicians to develop individualized traditional Chinese and Western medicine diagnosis and treatment strategies.
- Liver Cirrhosis /
- Diabetes Mellitus /
- TCM WM Therapy

HTML全文

参考文献(40)

[1]	HAMED AE, ELWAN N, NAGUIB M, et al. Diabetes association with liver diseases: An overview for clinicians[J]. Endocr Metab Immune Disord Drug Targets, 2019, 19(3): 274-280. DOI: 10.2174/1871530318666181116111945.
[2]	NATH P, ANAND AC. Hepatogenous diabetes: A primer[J]. J Clin Exp Hepatol, 2021, 11(5): 603-615. DOI: 10.1016/j.jceh.2021.04.012.
[3]	NISHIDA T, TSUJI S, TSUJII M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis[J]. Am J Gastroenterol, 2006, 101(1): 70-75. DOI: 10.1111/j.1572-0241.2005.00307.x.
[4]	MOREAU R, DELÈGUE P, PESSIONE F, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites[J]. Liver Int, 2004, 24(5): 457-464. DOI: 10.1111/j.1478-3231.2004.0991.x.
[5]	TIAN CY, HU H, ZHANG GY, et al. Recent developments in the diagnosis of hepatogenous diabetes[J]. Chin Gen Pract, 2021, 24(9): 1158-1164. DOI: 10.12114/j.issn.1007-9572.2021.00.068. 田彩云, 胡晗, 张国远, 等. 肝源性糖尿病的诊断研究进展[J]. 中国全科医学, 2021, 24(9): 1158-1164. DOI: 10.12114/j.issn.1007-9572.2021.00.068.
[6]	ADAMS LA, ARAUZ O, ANGUS PW, et al. Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant[J]. J Gastroenterol Hepatol, 2016, 31(5): 1016-1024. DOI: 10.1111/jgh.13240.
[7]	LIU TL, TROGDON J, WEINBERGER M, et al. Diabetes is associated with clinical decompensation events in patients with cirrhosis[J]. Dig Dis Sci, 2016, 61(11): 3335-3345. DOI: 10.1007/s10620-016-4261-8.
[8]	EL-SERAG HB, TRAN T, EVERHART JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma[J]. Gastroenterology, 2004, 126(2): 460-468. DOI: 10.1053/j.gastro.2003.10.065.
[9]	SHANIK MH, XU Y, SKRHA J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?[J]. Diabetes Care, 2008, 31(Suppl 2): s262-s268. DOI: 10.2337/dc08-s264.
[10]	UNOKI H, YAMAGISHI S. Advanced glycation end products and insulin resistance[J]. Curr Pharm Des, 2008, 14(10): 987-989. DOI: 10.2174/138161208784139747.
[11]	ROMERO-GÓMEZ M. Insulin resistance and hepatitis C[J]. World J Gastroenterol, 2006, 12(44): 7075-7080. DOI: 10.3748/wjg.v12.i44.7075.
[12]	EL-ZAYADI AR, SELIM OE, HAMDY H, et al. Association of chronic hepatitis C infection and diabetes mellitus[J]. Trop Gastroenterol, 1998, 19(4): 141-144. http://www.ncbi.nlm.nih.gov/pubmed/10228436
[13]	ZHAO CQ, GU HT, XING F, et al. Clinical features of post - hepatitis B liver cirrhosis associated with diabetes mellitus[J]. J Clin Hepatol, 2012, 28(6): 450-455. DOI: 10.3969/j.issn.1001-5256.2012.06.014. 赵长青, 顾宏图, 邢枫, 等. 乙型肝炎肝硬化合并糖尿病的临床特点[J]. 临床肝胆病杂志, 2012, 28(6): 450-455. DOI: 10.3969/j.issn.1001-5256.2012.06.014.
[14]	ADDEPALLY NS, GEORGE N, MARTINEZ-MACIAS R, et al. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis[J]. Dig Dis Sci, 2018, 63(12): 3498-3508. DOI: 10.1007/s10620-018-5265-3.
[15]	BOURSIER J, ANTY R, CARETTE C, et al. Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement[J]. Diabetes Metab, 2021, 47(5): 101272. DOI: 10.1016/j.diabet.2021.101272.
[16]	Chinese Diabetes Society. Clinical application guideline for blood glucose monitoring in China (2021 edition)[J]. Chin J Diabetes, 2021, 13(10): 936-948. DOI: 10.3760/cma.j.cn115791-20210810-00436. 中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(10): 936-948. DOI: 10.3760/cma.j.cn115791-20210810-00436.
[17]	LEE WG, WELLS CI, MCCALL JL, et al. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis[J]. Diabetes Metab Res Rev, 2019, 35(6): e3157. DOI: 10.1002/dmrr.3157.
[18]	RAN YZ, TONG XL. Treatment of hepatogenous diabetes based on intermingled stasis and heat[J]. Chin J Basic Med Tradit Chin Med, 2012, 18(5): 525-526. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201205027.htm 冉颖卓, 仝小林. 从瘀热互结论治肝源性糖尿病[J]. 中国中医基础医学杂志, 2012, 18(5): 525-526. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201205027.htm
[19]	ZHAO CQ, GU HT, XING F, et al. Study of TCM syndrome features in patients with liver cirrhosis combined with diabetes mellitus[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2007, 21(5): 38-40. DOI: 10.3969/j.issn.1008-861X.2007.05.012. 赵长青, 顾宏图, 邢枫, 等. 肝硬化合并糖代谢异常的中医证候特点研究[J]. 上海中医药大学学报, 2007, 21(5): 38-40. DOI: 10.3969/j.issn.1008-861X.2007.05.012.
[20]	LI Y, ZHAO CQ, GU HT, et al. Etiology and pathogenesis of hepatogenous diabetes based on the theory of "liver disease affecting the spleen"[J]. Chin J Basic Med Tradit Chin Med, 2013, 19(9): 1002-1005. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201309013.htm 李苑, 赵长青, 顾宏图, 等. 基于"肝病传脾"理论探讨肝源性糖尿病病因病机[J]. 中国中医基础医学杂志, 2013, 19(9): 1002-1005. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201309013.htm
[21]	SHEN Z, CHAI KF. Treatment of diabetes from aspect of spleen[J]. Henan Tradit Chin Med, 2009, 29(8): 745-747. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY200908012.htm 慎知, 柴可夫. 糖尿病从脾论治的意义及思考[J]. 河南中医, 2009, 29(8): 745-747. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY200908012.htm
[22]	ZHAO J, BAI LT, ZHENG HJ, et al. The idea of "treatment from the liver" in treatment of hepatogenous diabetes[J]. Beijing J Tradit Chin Med, 2018, 37(9): 839-842. DOI: 10.16025/j.1674-1307.2018.09.012. 赵静, 柏力萄, 郑慧娟, 等. 肝源性糖尿病"从肝论治"思路探讨[J]. 北京中医药, 2018, 37(9): 839-842. DOI: 10.16025/j.1674-1307.2018.09.012.
[23]	SUN J. Exploration of treating hepatogenic diabetes on traditional Chinese medicine[J]. Chin J Tradit Chin Med Pharm, 2002, 17(2): 100-101. DOI: 10.3969/j.issn.1673-1727.2002.02.014. 孙钧. 肝源性糖尿病的中医辨治探讨[J]. 中国医药学报, 2002, 17(2): 100-101. DOI: 10.3969/j.issn.1673-1727.2002.02.014.
[24]	SUN HY. Treatment of hepatogenous diabetes based on traditional Chinese medicine pathogenesis[J]. Guide China Med, 2008, 6(23): 295-297. DOI: 10.3969/j.issn.1671-8194.2008.23.224. 孙贺营. 肝源性糖尿病中医病机论治探源[J]. 中国医药指南, 2008, 6(23): 295-297. DOI: 10.3969/j.issn.1671-8194.2008.23.224.
[25]	HU JW, WU WB. Clinical observation on hepatocirrhosis patients glycometabolism disorder and syndrome-differentiating of TCM[J]. Liaoning J Tradit Chin Med, 2002, (12): 713-714. DOI: 10.3969/j.issn.1000-1719.2002.12.008. 胡坚文, 吴文彪. 肝硬变患者糖代谢异常与中医辨证的临床观察[J]. 辽宁中医杂志, 2002, (12): 713-714. DOI: 10.3969/j.issn.1000-1719.2002.12.008.
[26]	LI YP, SUN XY. An analysis of TCM pathological mechanism of diabetes caused by emotional disorders[J]. Clin J Chin Med, 2020, 12(1): 53-55. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLY202001019.htm 李玉萍, 孙新宇. 情志失调导致消渴病的中医病理机制探析[J]. 中医临床研究, 2020, 12(1): 53-55. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLY202001019.htm
[27]	BHAT A, SEBASTIANI G, BHAT M. Systematic review: Preventive and therapeutic applications of metformin in liver disease[J]. World J Hepatol, 2015, 7(12): 1652-1659. DOI: 10.4254/wjh.v7.i12.1652.
[28]	CHOUDHURY S, HIRSCHBERG Y, FILIPEK R, et al. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis[J]. J Clin Pharmacol, 2000, 40(6): 634-640. DOI: 10.1002/j.1552-4604.2000.tb05989.x
[29]	KIHARA Y, OGAMI Y, TABARU A, et al. Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose[J]. J Gastroenterol, 1997, 32(6): 777-782. DOI: 10.1007/BF02936954.
[30]	MACHA S, ROSE P, MATTHEUS M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment[J]. Diabetes Obes Metab, 2014, 16(2): 118-123. DOI: 10.1111/dom.12183.
[31]	KASICHAYANULA S, LIU X, ZHANG W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study[J]. Clin Ther, 2011, 33(11): 1798-1808. DOI: 10.1016/j.clinthera.2011.09.011.
[32]	SCHEEN AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications[J]. Diabetes Metab, 2019, 45(3): 213-223. DOI: 10.1016/j.diabet.2019.01.008.
[33]	American Diabetes Association Professional Practice Committee. Summary of revisions: Standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): s4-s7. DOI: 10.2337/dc22-Srev.
[34]	JENSEN L, KUPCOVA V, AROLD G, et al. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment[J]. Diabetes Obes Metab, 2018, 20(4): 998-1005. DOI: 10.1111/dom.13186.
[35]	LIU P, HU YY, LIU C, et al. Multi-centrally clinical trial of Fuzhenghuayu (Strengthening Healthy Qi to Solve Stagnation) capsules on liver filbrosis caused by chronic hepatitis B[J]. World Sci Technol Modern Tradit Chin Med, 2005, 7(1): 24-32. DOI: 10.3969/j.issn.1674-3849.2005.01.006. 刘平, 胡义扬, 刘成, 等. 扶正化瘀胶囊干预慢性乙型肝炎肝纤维化作用的多中心临床观察[J]. 世界科学技术-中医药现代化, 2005, 7(1): 24-32. DOI: 10.3969/j.issn.1674-3849.2005.01.006.
[36]	ZHAO CQ, GU HT, CHENG Y, et al. Applying Fuzheng Huayu Gantang comprehensive therapeutic program for treatment of post-hepatitis B liver cirrhosis complicated with glyco-metabolic abnormality[J]. Chin J Integr Trad West Med, 2008, 28(1): 24-27. DOI: 10.3321/j.issn:1003-5370.2008.01.008. 赵长青, 顾宏图, 成扬, 等. 扶正化瘀肝糖综合治疗方案治疗乙型肝炎后肝硬化合并糖代谢异常的临床研究[J]. 中国中西医结合杂志, 2008, 28(1): 24-27. DOI: 10.3321/j.issn:1003-5370.2008.01.008.
[37]	LUO Y, GUO W. Treatment of diabetes from the liver[J]. J Tradit Chin Med, 2015, 56(8): 719-720. DOI: 10.13288/j.11-2166/r.2015.08.023. 罗寅, 郭巍. 从肝论治糖尿病[J]. 中医杂志, 2015, 56(8): 719-720. DOI: 10.13288/j.11-2166/r.2015.08.023.
[38]	LIU Q, WEI JF. Research advances in the treatment of diabetes from the liver[J]. Guid J Tradit Chin Med Pharmacol, 2015, 21(18): 88-90. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB201518035.htm 刘琼, 卫家芬. 从肝论治糖尿病的研究进展[J]. 中医药导报, 2015, 21(18): 88-90. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB201518035.htm
[39]	HUA YX, CUI YZ. Research advances in the treatment of diabetes with depression from the liver and spleen[J]. Chin J EthoMed Ethnopharm, 2015, 24(18): 27-28, 31. https://www.cnki.com.cn/Article/CJFDTOTAL-MZMJ201518015.htm 华元鑫, 崔云竹. 从肝脾论治糖尿病合并抑郁症的研究进展[J]. 中国民族民间医药, 2015, 24(18): 27-28, 31. https://www.cnki.com.cn/Article/CJFDTOTAL-MZMJ201518015.htm
[40]	JING J, GONG M, DU N, et al. Therapy for hepatogenous diabetes based on "the Relation between Liver and Spleen"[J]. Western J Traditl Chin Med, 2014, 27(11): 1-3. DOI: 10.3969/j.issn.1004-6852.2014.11.001. 景婧, 宫嫚, 杜宁, 等. 从"肝脾相关"立论治疗肝源性糖尿病[J]. 西部中医药, 2014, 27(11): 1-3. DOI: 10.3969/j.issn.1004-6852.2014.11.001.